RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Respiratory Syncytial Virus Infections Clinical Trial

Official title:

A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum, in Healthy Third-trimester Pregnant Women and to Assess the Impact of Maternal Immunization on Infant Safety Through One Year of Life

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02247726
• Other study ID #: RSV-M-203
• Status: Completed
• Phase: Phase 2
• Start date: September 2014
• Est. completion date: July 2016

Study information

• Verified date: May 2022
• Source: Novavax
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunogenicity of an RSV-F protein nanoparticle vaccine, with aluminum, in healthy third-trimester pregnant women and to assess the impact of maternal immunization on infant safety through one year of life.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

Pregnant women must meet all of the following criteria to be eligible to participate:

1. =18 and =40 years-of-age.

2. Singleton pregnancy of 33 to 35 weeks gestation on the day of planned vaccination.

3. Good general maternal health as demonstrated by:

• Medical history (including history of adverse reactions to prior vaccines and allergies).
• Physical examination including at least vital signs (blood pressure, pulse, respirations, and oral temperature); weight; height; examination of the HEENT, cardiovascular, pulmonary, gastrointestinal (abdominal), musculoskeletal, lymphatic, and dermatologic organ systems; and documentation of fetal heart tones.
• Clinical laboratory parameters including normal blood urea nitrogen, creatinine, ALT, AST, total bilirubin, alkaline phosphatase (ALP), hemoglobin, white blood count, and platelet count; and serologic exclusion of infection with hepatitis B (HBV) and C (HCV) viruses and HIV (as required). Note that normal ranges for vital signs and clinical laboratory parameters will be based on third trimester values published in Sheffield et al. [2013] and/or reference ranges for the third trimester of pregnancy of the central laboratory.

4. Documentation that fulfills one of the following:

• Detailed (level II) second trimester or later anatomic ultrasound with no significant anatomic or growth abnormalities identified; OR
• Routine second trimester or later ultrasound with no significant anatomic or

growth abnormalities identified, PLUS at least one of the following:

• Normal first trimester screening (based on ultrasound + serum analytes); or
• Normal cell-free fetal DNA; or
• Normal chorionic villus sampling (CVS) or amniocentesis; or
• Normal second trimester maternal serum quadruple screen; or
• Normal first and second trimester screening using integrated, sequential, or contingency approach; or
• Abnormal first or second trimester screening followed by normal CVS, amniocentesis, or cell-free fetal DNA.

5. Able to understand, and both willing and physically able to comply with study procedures. This includes anticipation of reasonable geographic proximity to the study clinic and adequate transportation to comply with scheduled and unscheduled study follow-up visits.

6. Able and willing to provide written informed consent for themselves and infant. Exclusion Criteria: Pregnant women will be excluded if there is historical, physical examination, or laboratory

evidence of any of the following criteria:

1. Symptomatic cardiac or pulmonary disease requiring chronic drug therapy, including hypertension and asthma. Asthma will be exclusionary if the subject is receiving chronic systemic glucocorticoids at any dose or inhaled glucocorticoids at any dose >500µg per day of beclamethasone or fluticasone, or >800µg per day of budesonide.

2. Pre-pregnancy body mass index (BMI) of =35 or <18.5.

3. Hemoglobinopathy (including known sickle trait or thalassemias, even if asymptomatic) or blood dyscrasias.

4. Hepatic or renal dysfunction.

5. Established diagnosis of seizure disorder, regardless of therapy.

6. Auto-immune disease or known immunodeficiency syndrome.

7. Endocrine disorders, including (but not limited to) hyperthyroidism, untreated hypothyroidism, and glucose intolerance (e.g., diabetes mellitus type 1 or 2) antedating pregnancy, or occurring during pregnancy and requiring interventions other than diet for control.

8. History of major gynecologic or major abdominal surgery, including bariatric surgery.

9. Known HIV, HBV, or HCV infection, as assessed by serologic tests conducted during the current pregnancy or as a procedure during the screening period of the study.

10. Primary genital herpes simplex (HSV) infection during the current pregnancy.

11. Current alcohol or drug abuse.

12. Documentation that current pregnancy results from fertility treatments, rape, or incest.

13. Documentation that the infant will be a ward of the state or be released for adoption.

14. Neuro-psychiatric illness deemed likely to interfere with protocol compliance, safety reporting, or receipt of pre-natal care; or requiring treatment with psychotropic drugs.

15. History/presence of deep venous thrombosis or thromboembolism, or the use of anticoagulants during pregnancy.

16. Untreated red blood cell allo-immunization.

17. Prior stillbirth or neonatal death, or multiple (=3) spontaneous abortions.

18. Prior preterm delivery =34 weeks gestation or having ongoing intervention (medical/surgical) in current pregnancy to prevent preterm birth.

19. Greater than five (5) prior deliveries.

20. Previous infant with a known genetic disorder or major congenital anomaly.

21. Receipt of investigational drugs or immune globulins (with the exception of prophylactic anti-Rho D immune globulin) within six (6) months prior to the administration of the study vaccine.

22. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose =10mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted except for the limit established in exclusion criterion #1.

23. Any other physical, psychiatric or social condition which may, in the investigator's opinion, increase the risks of study participation to the maternal subject or the fetus/infant; or may lead to the collection of incomplete or inaccurate safety data.

Related Conditions & MeSH terms

• Respiratory Syncytial Virus Infections

Intervention

Drug:
• Saline Placebo (0.5mL injection)

• RSV F vaccine (0.5mL injection)

Locations

Country	Name	City	State
United States	Duke University	Durham	North Carolina
United States	Baylor College of Medicine	Houston	Texas
United States	Hutchinson Clinic, P.A.	Hutchinson	Kansas
United States	University of Kansas Medical Center Research Institute	Kansas City	Kansas
United States	Advanced Specialty Research	Nampa	Idaho
United States	Meridian Clinical Research	Norfolk	Nebraska
United States	Magee- Womens Hospital of UPMC	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Novavax

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Counts and proportions of maternal subjects with RSV-related respiratory illness as detected by active and passive surveillance.	In Maternal Subjects	Day 0 to Day 180
Other	Counts and proportions of infants with non-medically attended RSV-related respiratory illness as detected by active and passive surveillance.	In Infant Subjects	Birth to Day 365
Other	Counts and proportions of infants with medically attended, non-RSV LRTI as assessed by multiplex real time (RT)-PCR.	In Infant Subjects	Birth to Day 365
Primary	Counts and percentage of subjects with solicited injection site and systemic reactogenicity within seven days of vaccination.	In Maternal Subjects	Day 0 to Day D+180
Primary	Counts and percentage of subjects with unsolicited (local and systemic) adverse events (AE), unscheduled medically-attended adverse events (MAEs), and serious adverse events (SAEs) through delivery and six (6) months thereafter.	In Maternal Subjects	Day 0 to Day D+180
Primary	Clinical safety laboratory assessments of select serum chemistry and hematology parameters through delivery.	In Maternal Subjects	Screening to Day 14
Primary	Counts and percentage of subjects with post-immunization onset of specific complications of third-trimester pregnancy and delivery	In Maternal Subjects	Day 0 to Day 28 - 42
Primary	Counts and percentage of term healthy infants appropriate for gestational age.	In Infant subjects	Day 28 - 42
Primary	Neonatal SAEs (including congenital anomalies, respiratory failure, fever/infection, and neonatal death or other adverse events/complications that necessitate extended hospitalization).	In Infant Subjects	Birth to Day 365
Primary	Growth and development over one year	In Infant Subjects	Birth to Day Day 365
Primary	Counts and proportion of infants with unsolicited adverse events	In Infant Subjects	Birth to Day 365
Primary	Counts and proportions of infants with medically-attended RSV lower respiratory tract infection (LRTI), and age of onset of those infections.	In Infant Subjects	Birth to Day 365
Secondary	Immunogenicity as assessed by serum IgG antibody titers specific fro the F-Protein antigen.	In Infant Subjects	Birth to Day 180
Secondary	Serum antibody titers inhibiting binding of labeled palivizumab to RSV F protein.	In Infant Subjects	Birth to Day 180
Secondary	Serum microneutralization (MN) titers against RSV/A and B.previously referenced, but based on GMT.	In Infant Subjects	Birth to Day 180

External Links

•   Novavax, Inc.